Omeros CorpNASDAQ:OMER
- LAST PRICE3.8650
- TODAY'S CHANGE (%)-0.0150 (-0.3866%)
- Bid / Lots3.8000/ 3
- Ask / Lots3.9100/ 2
- Open / Previous Close3.8800 / 3.8800
- Day Range
- 52 Week Range
- Volume106,077
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 1115 | 3.9 |
| 09:36 ET | 610 | 3.905 |
| 09:38 ET | 401 | 3.86 |
| 09:39 ET | 624 | 3.89 |
| 09:41 ET | 100 | 3.895 |
| 09:43 ET | 263 | 3.91 |
| 09:45 ET | 1223 | 3.93 |
| 09:50 ET | 100 | 3.9 |
| 09:57 ET | 100 | 3.88 |
| 10:08 ET | 180 | 3.8704 |
| 10:17 ET | 440 | 3.87 |
| 10:28 ET | 200 | 3.86 |
| 10:32 ET | 604 | 3.8606 |
| 10:35 ET | 100 | 3.87 |
| 10:37 ET | 300 | 3.86 |
| 10:46 ET | 300 | 3.87 |
| 10:53 ET | 200 | 3.88 |
| 10:55 ET | 100 | 3.87 |
| 11:04 ET | 200 | 3.875 |
| 11:11 ET | 500 | 3.875 |
| 11:13 ET | 2200 | 3.8859 |
| 11:15 ET | 300 | 3.885 |
| 11:18 ET | 100 | 3.885 |
| 11:24 ET | 1358 | 3.87 |
| 11:29 ET | 100 | 3.875 |
| 11:31 ET | 200 | 3.87 |
| 11:33 ET | 100 | 3.87 |
| 11:40 ET | 100 | 3.87 |
| 11:44 ET | 100 | 3.87 |
| 11:47 ET | 400 | 3.88 |
| 11:49 ET | 108 | 3.89 |
| 12:12 ET | 100 | 3.9 |
| 12:14 ET | 200 | 3.9 |
| 12:18 ET | 8215 | 3.875 |
| 12:21 ET | 100 | 3.875 |
| 12:27 ET | 100 | 3.875 |
| 12:32 ET | 200 | 3.875 |
| 12:34 ET | 100 | 3.875 |
| 12:45 ET | 100 | 3.875 |
| 12:48 ET | 100 | 3.875 |
| 12:59 ET | 316 | 3.875 |
| 01:08 ET | 212 | 3.875 |
| 01:12 ET | 1563 | 3.84 |
| 01:15 ET | 100 | 3.845 |
| 01:19 ET | 200 | 3.86 |
| 01:24 ET | 100 | 3.845 |
| 01:33 ET | 214 | 3.845 |
| 01:37 ET | 1500 | 3.8331 |
| 01:46 ET | 100 | 3.83 |
| 01:48 ET | 100 | 3.835 |
| 01:50 ET | 326 | 3.84 |
| 01:55 ET | 2500 | 3.855 |
| 01:57 ET | 1719 | 3.87 |
| 02:00 ET | 200 | 3.88 |
| 02:08 ET | 213 | 3.87 |
| 02:09 ET | 100 | 3.87 |
| 02:15 ET | 500 | 3.855 |
| 02:18 ET | 212 | 3.855 |
| 02:20 ET | 100 | 3.85 |
| 02:29 ET | 600 | 3.85 |
| 02:31 ET | 1100 | 3.8588 |
| 02:33 ET | 1000 | 3.8543 |
| 02:38 ET | 230 | 3.85 |
| 02:40 ET | 137 | 3.849 |
| 02:42 ET | 312 | 3.85 |
| 02:45 ET | 100 | 3.84 |
| 02:49 ET | 100 | 3.845 |
| 02:54 ET | 212 | 3.845 |
| 02:58 ET | 700 | 3.87 |
| 03:00 ET | 316 | 3.87 |
| 03:03 ET | 100 | 3.86 |
| 03:05 ET | 100 | 3.85 |
| 03:07 ET | 600 | 3.87 |
| 03:09 ET | 6593 | 3.89 |
| 03:12 ET | 1321 | 3.86 |
| 03:21 ET | 215 | 3.875 |
| 03:25 ET | 100 | 3.88 |
| 03:27 ET | 100 | 3.88 |
| 03:30 ET | 219 | 3.875 |
| 03:34 ET | 1512 | 3.885 |
| 03:36 ET | 1425 | 3.87 |
| 03:38 ET | 400 | 3.87 |
| 03:41 ET | 5409 | 3.86 |
| 03:43 ET | 212 | 3.865 |
| 03:48 ET | 100 | 3.865 |
| 03:52 ET | 2269 | 3.85 |
| 03:54 ET | 1216 | 3.85 |
| 03:56 ET | 338 | 3.855 |
| 03:57 ET | 2620 | 3.855 |
| 03:59 ET | 5496 | 3.865 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 224.0M | -1.3x | --- |
Vicapsys Life Sciences Inc | 160.4M | -152.8x | --- |
Zura Bio Ltd | 222.9M | -2.1x | --- |
Tenaya Therapeutics Inc | 229.3M | -1.8x | --- |
Solid Biosciences Inc | 225.3M | -1.5x | --- |
Tectonic Therapeutic Inc | 232.1M | 1.9x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance, Treasurer
- David Borges
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $224.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-2.90 |
Book Value | $-0.41 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
